. Author manuscript; available in PMC: 2017 Apr 1.

Published in final edited form as: Curr Opin Immunol. 2016 Jan 19;39:52–58. doi: 10.1016/j.coi.2016.01.002

Table 1.

Proposed antigens for preventative cancer vaccines in the setting of premalignant disease

Candidate Antigens	Premalignant lesions (cancer type)
HPV16 E6 and E7	Cervical intraepithelial neoplasia (CIN) (cervical) Vulvar intraepithelial neoplasia (vulvar)
Cancer Testis (CT) antigens MAGE-A1-A4, NYESO-1, GAGE	Ductal carcinoma in situ (breast) Squamous dysplasia of the head and neck (SCCHN) Esophageal squamous carcinoma in situ (esophageal)
Her-2/neu	Ductal carcinoma in situ (breast) Colon adenomas (colorectal)
MUC1	Pancreatic intraepithelial neoplasia (PanIn) (pancreatic) Intraductal papillary mucinous neoplasms (IPMN) (pancreatic) Berrett’s Esophagus (esophageal) Adenomatous polyps (colon) Monoclonal gammopathy of undetermined significance (MGUS) and Asymptomatic multiple myeloma (AMM) (multiple myeloma) Bronchial preneoplasia (lung)
Mesothelin	Pancreatic intraepithelial neoplasia (PanIn) (pancreatic) Intraductal papillary mucinous neoplasms (IPMN) (pancreatic)
Cyclin B1	Bronchial preneoplasia (lung) Squamous dysplasia of the head and neck (SCCHN) Ductal carcinoma in situ (breast) Preneoplastic PSA negative stage (prostate)
SOX-2	Monoclonal gammopathy of undetermined significance (MGUS) and Asymptomatic multiple myeloma (AMM) (multiple myeloma)
EGFR	Bronchial preneoplasia (lung)